Bioblast Pharma announces entry into merger agreement to acquire Enlivex Therapeutics
Bioblast Pharma announced the execution of an agreement to acquire Enlivex Therapeutics, a VC-funded privately-held immunotherapy company. Upon closing of the transaction, the combined company will change its name to Enlivex Therapeutics, and its trading ticker will be modified appropriately. November 19, 2018